Compare Natera Inc. Common Stock (NTRA) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs ProShares Ultra Gold ETF — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while ProShares Ultra Gold ETF trades at $45.52 (market cap $730.54M). The key difference: Natera Inc. Common Stock is far larger — about 78.1× ProShares Ultra Gold ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and ProShares Ultra Gold ETF for 25 Days on average.
| NTRA | UGL | |
|---|---|---|
Market Cap | $57.03B | $730.54M |
Volume | 1,131,157 | 4,212,910 |
Sector | Health | Leveraged / Inverse |
52-Week High | $425.64 | $85.62 |
52-Week Low | $179.42 | $42.79 |
Typical Hold Time | 0 Days | 25 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
UGL is trading at $45.70, down 0.39% on the day, with a bearish technical signal driven by moving averages and key indicators like ADX. Financial ratios are unavailable, limiting fundamental assessment. Recent news highlights gold price volatility amid shifting Fed rate expectations and Treasury yield pressures, influencing sentiment.
The outlook remains cautious due to technical weakness and macroeconomic headwinds. Risks include persistent rate-hike uncertainty and gold market sensitivity. Investment potential hinges on future financial disclosures and gold price stabilization, but current data gaps and bearish signals suggest limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
